1 / 7

Ensuring Timely Treatment Stable Supply of Terbium-161

The stable supply of Terbium-161 (Tb-161) is crucial for ensuring timely access to next-generation cancer treatments. Tb-161u2019s promising potential as a targeted therapy for various cancers hinges on consistent availability for clinical use. Reliable sourcing of this isotope enables healthcare providers to offer cutting-edge treatment options without delays, improving patient outcomes and expanding the possibilities for personalized cancer care. This article highlights the importance of a stable Tb-161 supply chain... More information available at https://nuclearmedicinetherapy.in/

Nuclearmedicinetherapy
Download Presentation

Ensuring Timely Treatment Stable Supply of Terbium-161

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Nuclear Medicine Centre FMRi Gurugram INDIA Dr. Ishita B Sen Ensuring Timely Treatment: Stable Supply of Terbium-161 www.nuclearmedicinetherapy.in

  2. What is Terbium-161? • A next-generation radionuclide emitting beta particles, Auger electrons, and conversion electrons. • Therapeutic Potential: • Enhanced DNA damage in cancer cells, especially effective against micrometastases. • Comparison with Lutetium-177: • Similar half-life (~6.9 days) but with additional electron emissions, potentially enhancing therapeutic efficacy.​

  3. Production and Supply Chain • Production Method: • Generated by neutron irradiation of enriched Gadolinium-160 (^160Gd) in nuclear reactors. • Global Supplier: • TerThera, based in the Netherlands, is the leading supplier. • Supply at Our Centre: • Fortis Memorial Research Institute (FMRI), Gurugram, receives Terbium-161 shipments twice a month, ensuring regular availability for patient therapy planning.

  4. Clinical Applications • Targeted Cancers: • Prostate cancer (via PSMA ligands), neuroendocrine tumors (via DOTATATE), and other solid tumors where FAPI or other ligands are applicable. • Therapy Protocol: • Patients undergo a PSMA or DOTATOC scan for eligibility. • Administered as a short intravenous infusion via a cannula. • Supportive care includes hydration and sometimes amino acids to protect the kidneys. • Post-therapy, patients are scanned multiple times for image-based dosimetry. ​

  5. Advantages of Stable Supply • Timely Treatment: • Regular shipments allow for consistent scheduling of therapy sessions. • Enhanced Patient Outcomes: • Minimizes delays, leading to better disease management and improved quality of life. • Operational Efficiency: • Facilitates seamless coordination among multidisciplinary teams.​

  6. Conclusion • Summary: • The stable supply of Terbium-161 at FMRI ensures timely and effective treatment for patients, positioning the centre at the forefront of nuclear medicine therapy. • Future Outlook: • Continued commitment to maintaining a robust supply chain will further enhance patient care and treatment outcomes.​

  7. For more information talk to Dr. Ishita B Sen today. dr.ishitasen@nuclearmedicinetherapy.in +91 8700 668 431 www.nuclearmedicinetherapy.in

More Related